Relmada Therapeutics, Inc. (RLMD)
4.17
-0.07
(-1.65%)
USD |
NASDAQ |
Dec 08, 16:00
4.185
+0.02
(+0.36%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 305.80M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 811.5% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 32.31 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.50% |
Profile
| Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL. |
| URL | http://www.relmada.com |
| Investor Relations URL | https://www.relmada.com/for-investors |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL. |
| URL | http://www.relmada.com |
| Investor Relations URL | https://www.relmada.com/for-investors |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |